Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation

WASHINGTON--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease.

The data at TCT on Edwards innovations underscore our commitment to scientific leadership and our focus to bring impactful and life-saving structural heart therapies to patients and physicians, said Bernard Zovighian, Edwards CEO. This new clinical evidence also advances Edwards opportunities within both TAVR and TMTT to treat more patients with our advanced technologies and support long-term,... More

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

WASHINGTON--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The data, presented during the late-breaking clinical trial sessions at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, included the full cohort of 400 patients. TRISCEND II trial one-year primary endpoint outcomes will be... More

Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

WASHINGTON--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared with guideline-recommended clinical surveillance. Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF)... More